Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H5O7.Ga |
Molecular Weight | 256.0279 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[67Ga+3].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
InChI
InChIKey=YEEGWNXDUZONAA-RYDPDVNUSA-K
InChI=1S/C6H8O7.Ga/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;+3/p-3/i;1-3
Gallium citrate Ga 67 is the citrate salt of the radioisotope gallium Ga 67. Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metastatic tumors and focal sites of inflammation, allowing scintigraphic localization. Ga-67 scintigraphy (GS) cannot differentiate between tumor and acute inflammation. Gallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | GALLIUM CITRATE GA 67 Approved UseGallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Launch Date1976 |
|||
Primary | GALLIUM CITRATE GA 67 Approved UseGallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Launch Date1976 |
|||
Primary | GALLIUM CITRATE GA 67 Approved UseGallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Launch Date1976 |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QV09HX01
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
||
|
NCI_THESAURUS |
C1446
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
||
|
NDF-RT |
N0000000205
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
||
|
NDF-RT |
N0000177914
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
||
|
WHO-ATC |
V09HX01
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
272758
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY | |||
|
DTXSID70194107
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY | |||
|
255-248-4
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY | |||
|
Gallium Citrate Ga 67
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY | |||
|
m5649
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY | Merck Index | ||
|
41183-64-6
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY | |||
|
4560
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY | |||
|
1546372
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
ALTERNATIVE | |||
|
DB06784
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY | |||
|
100000090307
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY | |||
|
SUB02307MIG
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY | |||
|
65430
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY | |||
|
4LJK511Z86
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110553
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY | |||
|
SUB07873MIG
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY | |||
|
3744
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY | |||
|
4LJK511Z86
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY | |||
|
C47547
Created by
admin on Sat Dec 16 16:19:59 GMT 2023 , Edited by admin on Sat Dec 16 16:19:59 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD